These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1359 related items for PubMed ID: 16818707

  • 1. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 2. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 3. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
    Das K, Lorena PD, Ng LK, Lim D, Shen L, Siow WY, Teh M, Reichardt JK, Salto-Tellez M.
    Endocr Relat Cancer; 2010 Sep 01; 17(3):757-70. PubMed ID: 20519274
    [Abstract] [Full Text] [Related]

  • 4. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B, Vellaichamy A, Tomlins SA, Wang R, Cao Q, Lonigro RJ, Pienta KJ, Varambally S.
    Prostate; 2012 Oct 01; 72(14):1542-9. PubMed ID: 22415461
    [Abstract] [Full Text] [Related]

  • 5. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
    Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS.
    J Urol; 2004 Sep 01; 172(3):915-9. PubMed ID: 15310997
    [Abstract] [Full Text] [Related]

  • 6. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
    Shao TC, Li H, Ittmann M, Cunningham GR.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1521-7. PubMed ID: 17707058
    [Abstract] [Full Text] [Related]

  • 7. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
    Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB.
    Prostate; 2003 Oct 01; 57(2):134-9. PubMed ID: 12949937
    [Abstract] [Full Text] [Related]

  • 8. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, Bologna M.
    J Urol; 2008 Jul 01; 180(1):367-72. PubMed ID: 18499161
    [Abstract] [Full Text] [Related]

  • 9. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct 01; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 10. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN, Schröder FH.
    BJU Int; 2009 Nov 01; 104(9):1191-7. PubMed ID: 19624596
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2284-9. PubMed ID: 19080333
    [Abstract] [Full Text] [Related]

  • 12. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
    Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, Steinhoff G, Fleshner N, Bostwick D, Thomas L, Rittmaster R.
    Prostate; 2006 Nov 01; 66(15):1674-85. PubMed ID: 16927304
    [Abstract] [Full Text] [Related]

  • 13. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct 01; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 14. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
    Maria McCrohan A, Morrissey C, O'Keane C, Mulligan N, Watson C, Smith J, Fitzpatrick JM, Watson RW.
    Cancer; 2006 Jun 15; 106(12):2743-52. PubMed ID: 16703599
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.
    Schmidt LJ, Ballman KV, Tindall DJ.
    Prostate; 2007 Jul 01; 67(10):1111-20. PubMed ID: 17477363
    [Abstract] [Full Text] [Related]

  • 16. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
    Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ.
    Eur Urol; 2008 Feb 01; 53(2):244-52. PubMed ID: 18006217
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
    Gupta S, Wang Y, Ramos-Garcia R, Shevrin D, Nelson JB, Wang Z.
    Prostate; 2010 Oct 01; 70(14):1575-85. PubMed ID: 20564326
    [Abstract] [Full Text] [Related]

  • 18. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB, Nelson JB, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [Abstract] [Full Text] [Related]

  • 19. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
    Opoku-Acheampong AB, Nelsen MK, Unis D, Lindshield BL.
    PLoS One; 2012 Dec 01; 7(1):e29068. PubMed ID: 22242155
    [Abstract] [Full Text] [Related]

  • 20. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
    Makridakis N, Reichardt JK.
    J Mol Endocrinol; 2005 Jun 01; 34(3):617-23. PubMed ID: 15956333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.